Belite BioADR (NASDAQ: BLTE) — Perfil da empresa, notícias e dados financeiros
Belite Bio is a biotechnology firm developing therapies for eye diseases and metabolic disorders through clinical trials.
Belite BioADR
Belite Bio (NASDAQ:BLTE) is a biotechnology firm focused on developing therapeutic drugs for the treatment of eye diseases and metabolic disorders. Primarily operating in the research and development sector, the company is dedicated to advancing its portfolio of innovative treatments through clinical trials, with a keen eye on addressing unmet medical needs. Among its key projects are treatments aimed at tackling Age-related Macular Degeneration (AMD) and Stargardt Disease, highlighting its commitment to improving quality of life for patients with serious conditions. Belite Bio's objectives include the successful progress of their drug candidates through regulatory approvals, aiming for commercialization to make a significant impact on healthcare.
Resumo
Operações
Produtos e/ou serviços de Belite BioADR
- LBS-008, a once-a-day oral therapy for the treatment of Stargardt Disease, aiming to slow down vision loss.
- LBS-009, an investigational treatment focused on Best disease and other macular degenerations.
- Development of advanced treatments for Geographic Atrophy, targeting age-related macular degeneration.
- Research into therapies for Dry Age-Related Macular Degeneration (Dry AMD), seeking to prevent or slow progression.
- Initiatives aimed at tackling Inherited Retinal Diseases (IRDs), with a focus on genetic therapies.
- Pipeline expansion into Wet Age-Related Macular Degeneration (Wet AMD), exploring new drug candidates.
equipe executiva do Belite BioADR
- Yu-Hsin LinChairman of the Board of Directors & CEO
- Hao-Yuan ChuangCFO & Director
- Nathan L. MataChief Scientific Officer
- Hendrik P.N. SchollChief Medical Officer
- Kelly KilpatrickChief Commercial Officer
Últimas notícias sobre a Belite BioADR
Belite Bio files Japan NDA for drug
United StatesBelite Bio NDA accepted for Stargardt disease drug
United StatesBelite Bio advances FDA rolling submission for Stargardt disease candidate
United StatesBelite Bio reports positive Phase 3 DRAGON results with 35.7% reduction in macular lesion
United States
Principais indicadores financeiros
Resultados divulgados pela Belite BioADR, em USD.
- Cap. de mercado
- 6 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -2.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -84,2 mi | -77,6 mi | |
| 0 | -40 mi | -36,1 mi | |
| 0 | -31,7 mi | -31,6 mi | |
| 0 | -12,8 mi | -12,6 mi |